• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比索洛尔在健康志愿者以及肾脏或肝脏疾病患者重复口服给药期间的药代动力学。

Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.

作者信息

Kirch W, Rose I, Demers H G, Leopold G, Pabst J, Ohnhaus E E

出版信息

Clin Pharmacokinet. 1987 Aug;13(2):110-7. doi: 10.2165/00003088-198713020-00003.

DOI:10.2165/00003088-198713020-00003
PMID:2887325
Abstract

The pharmacokinetics of bisoprolol were investigated following oral administration of 10mg once daily for 7 days in 8 healthy subjects, in 14 patients with different degrees of renal impairment and in 18 patients with liver disease. In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed. 5.21 mg/24 hours of unchanged bisoprolol were recovered following urinary excretion during the dosage interval. In 11 patients with renal impairment (mean CLCR = 28 +/- 5 ml/min/1.72m2) half-life was prolonged to 18.5 hours, and peak and trough concentrations were 74 and 32 micrograms/L, respectively. Correspondingly, urinary excretion decreased to 3.35 mg/24 hours and total body clearance to 7.8 L/h. In uraemic patients (CLCR less than 5 ml/min/1.73m2) the total clearance of bisoprolol was 5.0 L/h and the elimination half-life was 24.2 hours. In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h. The present study indicates that in patients with impairment of kidney or liver function accumulation of bisoprolol above a factor of 2 did not occur. However, in the terminal stages of insufficiency of kidney or liver function bisoprolol dosage should not exceed 10mg.

摘要

在8名健康受试者、14名不同程度肾功能损害患者和18名肝病患者中,每日口服一次10mg比索洛尔,连续7天,研究了其药代动力学。在健康受试者中,观察到稳态峰浓度和谷浓度分别为52微克/升和11微克/升,消除半衰期为10.0小时,全身清除率为14.2升/小时。在给药间隔期间,经尿液排泄回收的未变化比索洛尔为5.21mg/24小时。在11名肾功能损害患者(平均肌酐清除率=28±5ml/min/1.72m²)中,半衰期延长至18.5小时,峰浓度和谷浓度分别为74和32微克/升。相应地,尿液排泄降至3.35mg/24小时,全身清除率降至7.8升/小时。在尿毒症患者(肌酐清除率小于5ml/min/1.73m²)中,比索洛尔的总清除率为5.0升/小时,消除半衰期为24.2小时。在肝硬化患者中,半衰期增至13.5小时,稳态峰浓度和谷浓度分别增至62和22微克/升,全身清除率降至10.8升/小时。本研究表明,在肾功能或肝功能损害患者中,比索洛尔未出现超过2倍的蓄积。然而,在肾功能或肝功能不全的终末期,比索洛尔剂量不应超过10mg。

相似文献

1
Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.比索洛尔在健康志愿者以及肾脏或肝脏疾病患者重复口服给药期间的药代动力学。
Clin Pharmacokinet. 1987 Aug;13(2):110-7. doi: 10.2165/00003088-198713020-00003.
2
Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.比索洛尔(一种新型高β1选择性肾上腺素能受体拮抗剂)的基础药代动力学
J Clin Pharmacol. 1986 Nov-Dec;26(8):616-21. doi: 10.1002/j.1552-4604.1986.tb02959.x.
3
The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance.比索洛尔(10毫克)在肾功能不全患者中的单剂量药代动力学:平衡清除率的临床意义。
Eur Heart J. 1987 Dec;8 Suppl M:15-22. doi: 10.1093/eurheartj/8.suppl_m.15.
4
Interaction of bisoprolol with cimetidine and rifampicin.比索洛尔与西咪替丁和利福平的相互作用。
Eur J Clin Pharmacol. 1986;31(1):59-62. doi: 10.1007/BF00870987.
5
Balanced pharmacokinetics and metabolism of bisoprolol.比索洛尔的药代动力学和代谢平衡
J Cardiovasc Pharmacol. 1986;8 Suppl 11:S16-20. doi: 10.1097/00005344-198511001-00003.
6
Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.比索洛尔-14C在三种动物物种和人类中的药代动力学及代谢情况。
J Cardiovasc Pharmacol. 1986;8 Suppl 11:S21-8. doi: 10.1097/00005344-198511001-00004.
7
Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.慢性肾衰竭患者和健康志愿者单次口服他林洛尔后的药代动力学及稳态药代动力学
Int J Clin Pharmacol Ther. 2001 Feb;39(2):61-6. doi: 10.5414/cpp39061.
8
Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease.
Eur Heart J. 1987 Dec;8 Suppl M:23-9. doi: 10.1093/eurheartj/8.suppl_m.23.
9
Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.比索洛尔与卡维地洛在健康犬体内药代动力学特性的比较。
Am J Vet Res. 2008 Dec;69(12):1659-63. doi: 10.2460/ajvr.69.12.1659.
10
Pharmacokinetics of epanolol (ICI 141,292) in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment.依泮洛尔(ICI 141,292)在健康年轻志愿者中的药代动力学以及老年心绞痛患者、肾或肝功能损害受试者的比较数据。
Drugs. 1989;38 Suppl 2:10-7. doi: 10.2165/00003495-198900382-00005.

引用本文的文献

1
Optimizing Cardiovascular Outcomes With Bisoprolol: An Evidence-Based Perspective.从循证角度看比索洛尔对心血管结局的优化作用
Cureus. 2025 Aug 7;17(8):e89579. doi: 10.7759/cureus.89579. eCollection 2025 Aug.
2
Monitoring Serum Bisoprolol Concentrations in Patients With Heart Failure With Reduced Ejection Fraction: Results of a Pilot Study From Routine Health Care.监测射血分数降低的心力衰竭患者的血清比索洛尔浓度:一项常规医疗保健的初步研究结果
Pharmacol Res Perspect. 2025 Jun;13(3):e70089. doi: 10.1002/prp2.70089.
3
Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K4.3 (I) Channel Isoforms.

本文引用的文献

1
Pharmacokinetics of atenolol in relation to renal function.阿替洛尔的药代动力学与肾功能的关系。
Eur J Clin Pharmacol. 1981 Jan;19(1):65-71. doi: 10.1007/BF00558387.
2
Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.肝硬化患者中美托洛尔的药代动力学
Clin Pharmacokinet. 1981 Sep-Oct;6(5):375-88. doi: 10.2165/00003088-198106050-00004.
3
The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.肾功能对醋丁洛尔及其主要N-乙酰代谢产物的血浆水平和尿排泄的影响。
卡维地洛、美托洛尔和比索洛尔对心脏 K4.3(I)通道同工型的差异作用。
Int J Mol Sci. 2023 Sep 8;24(18):13842. doi: 10.3390/ijms241813842.
4
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.体外治疗β-肾上腺素能拮抗剂中毒:EXTRIP 工作组的系统评价和建议。
Crit Care. 2021 Jun 10;25(1):201. doi: 10.1186/s13054-021-03585-7.
5
Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol.应用生理基于生物药剂学模型理解溶出差异对即释产品体内性能的影响:以比索洛尔为例。
CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):622-632. doi: 10.1002/psp4.12634. Epub 2021 Jun 3.
6
Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers - drug classes with low adherence in antihypertensive therapy.评估利尿剂和β受体阻滞剂治疗药物监测中的剂量相关浓度方法-抗高血压治疗中低依从性的药物类别。
Sci Rep. 2019 Oct 30;9(1):15652. doi: 10.1038/s41598-019-52164-y.
7
Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.比索洛尔在稳定型冠状动脉疾病患者中的群体药代动力学分析
Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):35-44. doi: 10.1007/s13318-017-0414-1.
8
Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease.加洛帕米在脂肪肝疾病患者中的处置、消除及血流动力学效应
Clin Drug Investig. 1995 Dec;10(6):337-43. doi: 10.2165/00044011-199510060-00004.
9
Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.比索洛尔在慢性心力衰竭患者中的药代动力学与身体成分:一项纵向研究。
Eur J Clin Pharmacol. 2016 Jul;72(7):813-22. doi: 10.1007/s00228-016-2041-1. Epub 2016 Mar 21.
10
In Silico comparison between metoprolol succinate and bisoprolol on 24-hour systolic blood pressures.琥珀酸美托洛尔与比索洛尔24小时收缩压的计算机模拟比较
Drugs R D. 2014 Dec;14(4):325-32. doi: 10.1007/s40268-014-0073-5.
Clin Nephrol. 1982 Aug;18(2):88-94.
4
Clinical experience with atenolol in patients with chronic liver disease.阿替洛尔在慢性肝病患者中的临床经验。
J Clin Pharmacol. 1983 Apr;23(4):171-7. doi: 10.1002/j.1552-4604.1983.tb02721.x.
5
Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.美托洛尔在肾功能受损患者中的药代动力学和药效学特性。
Clin Pharmacokinet. 1980 Mar-Apr;5(2):169-80. doi: 10.2165/00003088-198005020-00004.
6
Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.新型β肾上腺素能受体拮抗剂比索洛尔在麻醉犬和豚鼠体内的β1选择性
J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1156-60.
7
Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.比索洛尔(一种新型高β1选择性肾上腺素能受体拮抗剂)的基础药代动力学
J Clin Pharmacol. 1986 Nov-Dec;26(8):616-21. doi: 10.1002/j.1552-4604.1986.tb02959.x.
8
Determination of the new beta-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography.用高效液相色谱法测定血浆和尿液中新型β受体阻滞剂比索洛尔以及美托洛尔、阿替洛尔和普萘洛尔的含量。
J Chromatogr. 1986 Oct 31;382:215-24. doi: 10.1016/s0378-4347(00)83519-7.
9
Interaction of bisoprolol with cimetidine and rifampicin.比索洛尔与西咪替丁和利福平的相互作用。
Eur J Clin Pharmacol. 1986;31(1):59-62. doi: 10.1007/BF00870987.
10
Pharmacokinetics of atenolol in patients with renal impairment.阿替洛尔在肾功能损害患者中的药代动力学。
Eur J Clin Pharmacol. 1977 Nov 14;12(3):175-80. doi: 10.1007/BF00609856.